Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30774783 | 0.90 | HTR6 (0.38) | SLC22A12AKT1PIK3CAMTORHSD11B1 | |
| SCHEMBL30773994 | 0.90 | SLC22A12 (0.41) | SLC22A12KDM1AHSD11B1 | |
| SCHEMBL30774765 | 0.87 | CYP11B1 (0.40) | SLC22A12KDM1APIK3CA | |
| SCHEMBL30774387 | 0.85 | SLC22A12 (0.46) | SLC22A12KDM1AMEN1HSD11B1 | |
| SCHEMBL30774471 | 0.84 | PKM (0.41) | SLC22A12 | |
| SCHEMBL30773947 | 0.83 | HTR6 (0.43) | — | |
| SCHEMBL30774432 | 0.82 | USP30 (0.42) | KDM4ETP53KDM1AMEN1CHEK1 | |
| SCHEMBL30774394 | 0.82 | KDM1A (0.39) | SLC22A12KDM1AHRH3 | |
| SCHEMBL30773946 | 0.82 | DPP4 (0.37) | KDM1AMEN1ALDH1A1HRH3 | |
| SCHEMBL30773982 | 0.81 | EGLN1 (0.41) | SLC22A12KDM1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | claimed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | claimed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024061371-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州威诺森医药科技有限公司 | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | SLC22A12 3869/4885KDM4E 1112/4885TP53 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.